<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="57012">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01893333</url>
  </required_header>
  <id_info>
    <org_study_id>NSRH_Cxca</org_study_id>
    <nct_id>NCT01893333</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of Nerve-sparing Radical Hysterectomy in Cervical Cancer</brief_title>
  <acronym>NSRHCXCA</acronym>
  <official_title>The Efficacy and Safety of Nerve-sparing Radical Hysterectomy in Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <authority>South Korea: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To develope nerve sparing radical hysterectomy for treatment of cervical cancer to minimize
      the complication of radical hysterectomy and to maximize quality of life and to evaluate the
      feasibility and efficacy by prospective randomized trial.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Incidence of bladder dysfunction after surgery</measure>
    <time_frame>5 days after the surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Remove foley catheter and measure the residual urine volume Measure how long it took to be residual urine volume under 50 mL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>rectal &amp; anal function after surgery</measure>
    <time_frame>6, 12 months after surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual function</measure>
    <time_frame>6, 12 months after surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>6, 12 months after surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>operative time</measure>
    <time_frame>immediately after surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>amount of bleeding in operation</measure>
    <time_frame>immediately after surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>frequency of blood transfusion</measure>
    <time_frame>within 1 week after surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>amount of blood transfusion</measure>
    <time_frame>within 1 week after surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative complication</measure>
    <time_frame>within 1 month after surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time from surgery to return to work</measure>
    <time_frame>within 1 month after surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>management cost</measure>
    <time_frame>within 1 week after surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>size of resected parametrial tissue</measure>
    <time_frame>immediately after surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2year disease free survival</measure>
    <time_frame>2 year after treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">146</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Nerve sparing radical hysterectomy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sparing hypogastric nerve
sparing pelvic splanchnic nerve ad pelvic plexus in cardinal ligament
sparing distal part of hypogastric nerve and vesical branch of pelvic splanchnic nerve</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radical hysterectomy group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional radical hysterectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Nerve sparing radical hysterectomy</intervention_name>
    <description>Nerve sparing radical hysterectomy
sparing hypogastric nerve
sparing pelvic splanchnic nerve ad pelvic plexus in cardinal ligament
sparing distal part of hypogastric nerve and vesical branch of pelvic splanchnic nerve</description>
    <arm_group_label>Nerve sparing radical hysterectomy group</arm_group_label>
    <arm_group_label>Radical hysterectomy group</arm_group_label>
    <other_name>Nerve sparing radical hysterectomy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically diagnosed cervical cancer

          -  FIGO stage IA2-IIA

          -  Diameter of tumor is less than 4cm on exam

          -  One of hitological type written below squamous cell carcinoma, adenocarcinoma,
             adenosquamous cell carcinoma

          -  Age between 18-70

          -  Performance status; GOG 0-1

          -  Normal hematological, hepatic, nephrologic function WBC ≥ 4000 cells/mm3 Platelet ≥
             100,000 /mm3 Hemoglobin ≥ 8.0 gm/dL Serum creatinin ≤ 1.3 mg/dL Serum bilirubin ≤ 1.5
             mg/dL SBOT/SGPT and Alkaline phoaphatase &lt; normal X 3

          -  Patient with informed consent

        Exclusion creteria:

          -  Small cell carcinoma

          -  Unable to perform surgery because of severe underlying medical disease severe heart
             disease, congestive heart failure/severe pulmonary disease, pulmonary failure/ active
             bacterial infectio which needs non oral antibiotic therapy/ associated with other
             severe medical diseases

          -  Prior chemotherapy or radiotherapy

          -  Severe bladder funtion abnormality

          -  Double primary malignant tumor

          -  Psychiatric problems

          -  Pregnant or breast feeding status

          -  Legally unable to participate clinical trial

          -  When there is a Doctor's decision that patient is unable to participate clinical
             trial
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joo-Hyun Nam, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joo-Hyun Nam, M.D., Ph.D.</last_name>
    <phone>82-2-3010-3633</phone>
    <email>jhnam@amc.seoul.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joo-Hyun Nam, M.D., Ph.D.</last_name>
      <phone>82-2-3010-3633</phone>
      <email>jhnam@amc.seoul.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 2, 2013</lastchanged_date>
  <firstreceived_date>June 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Joo-Hyun Nam</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>cervical cancer</keyword>
  <keyword>nerve sparing radical hysterectomy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
